J.P. Morgan Day Three: 2023 Is A Year Of Commercial Challenges
Humira's LOE, Gene Therapy & Alzheimer's Launches Are Major Milestones For 2023
Daily notebook from the J.P. Morgan Healthcare Conference: Gene therapy Vertex enters pricing negotiations on gene therapy, Sanofi sees opportunity in hemophilia despite new gene therapy, and AbbVie raises guidance ahead of the introduction of Humira biosimilars. Plus ICER's Steven Pearson and former Biogen CEO George Scangos weigh in on Alzheimer's developments.
